§ 01 Overview
Overview
Non-peptide oral GLP-1 agonist in late Phase III trials, offering daily pill dosing without the restrictions of oral semaglutide.
Phase III ACHIEVE program read out in 2024–2025 with strong efficacy signals.
§ 02 Mechanism
Mechanism of action
Orforglipron binds the GLP-1 receptor as a non-peptide small molecule. Unlike oral semaglutide, it does not require a protective absorption enhancer or fasted administration.
- 01Convenient oral daily dosing
- 02Weight loss comparable to injectable GLP-1s in Phase II
- 03Potential for broader access given oral form
§ 03 Dosing
Dosing protocol
Standard Protocol
- Dose Range
- 7 – 45 mg daily
- Starting Dose
- 3 mg daily
- Route
- Oral
- Timing
- Any time
- Frequency
- Daily
- Cycle
- Titrate every 4 weeks.
§ 04 Evidence
Evidence & research
Phase III ACHIEVE program read out in 2024–2025 with strong efficacy signals.
FDA Status
Investigational. Filed with FDA in 2025.
§ 06 News
In the news
8 articles from the last 12 months · updates hourly
Oral GLP-1 Orforglipron Performs Well in Phase 3 T2D Trials - Medscape
Oral GLP-1 Orforglipron Performs Well in Phase 3 T2D Trials Medscape
Eli Lilly's New Oral GLP-1 Orforglipron Beats Semaglutide In Diabetes Trials; FDA Filing Near - NDTV
Eli Lilly's New Oral GLP-1 Orforglipron Beats Semaglutide In Diabetes Trials; FDA Filing Near NDTV
Lilly’s orforglipron outperforms oral semaglutide in Phase 3 diabetes trial - Express Pharma
Lilly’s orforglipron outperforms oral semaglutide in Phase 3 diabetes trial Express Pharma
Lilly’s oral GLP-1 drug Orforglipron outperforms Semaglutide in phase 3 diabetes trial - Indian Pharma Post
Lilly’s oral GLP-1 drug Orforglipron outperforms Semaglutide in phase 3 diabetes trial Indian Pharma Post
Oral Orforglipron Added to Basal Insulin Cuts HbA1c in Type 2 Diabetes - AJMC
Oral Orforglipron Added to Basal Insulin Cuts HbA1c in Type 2 Diabetes AJMC
ACHIEVE Trials Demonstrate Comparative Benefits of Novel, Small-Molecule Oral GLP-1 RA, Expanding Oral Treatment Options for Patient Population in Need of Alternative Solutions - Lelezard
ACHIEVE Trials Demonstrate Comparative Benefits of Novel, Small-Molecule Oral GLP-1 RA, Expanding Oral Treatment Options for Patient Population in Need of Alternative Solutions Lelezard
Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials - investor.lilly.com
Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials investor.lilly.com
ACHIEVE-5: Orforglipron Improves Glycemic Control, Weight in T2D on Basal Insulin - HCPLive
ACHIEVE-5: Orforglipron Improves Glycemic Control, Weight in T2D on Basal Insulin HCPLive
§ 07 Sourcing
Sourcing & supply
Regulatory status
Investigational, no compounding path
Currently in active clinical trials. No compounding pathway. No brand product. The only US channels are RUO vendors that the FDA has targeted with warning letters. Assume any sourcing carries significant regulatory and quality risk.
No suppliers in our directory currently stock this compound. For investigational or research-only compounds, legitimate channels may not exist outside clinical trials.
Browse full supplier directory§ 09 Safety
Safety & side effects
Side effects
- 01Nausea
- 02Diarrhea
- 03Constipation
Contraindications
None specified.